These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

947 related items for PubMed ID: 29754771

  • 1. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM, Pfirrmann V, Huenecke S, Bremm M, Bonig H, Kvasnicka HM, Klingebiel T, Bader P, Rettinger E.
    Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders.
    Hong J, Ni J, Ruan M, Yang M, Dong Q, Li Q.
    Int J Hematol; 2020 Jun; 111(6):851-857. PubMed ID: 32162095
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V, Oelsner S, Rettinger E, Huenecke S, Bonig H, Merker M, Wels WS, Cinatl J, Schubert R, Klingebiel T, Bader P.
    Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM.
    Recent Results Cancer Res; 2002 Aug; 159():123-33. PubMed ID: 11785836
    [Abstract] [Full Text] [Related]

  • 9. Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease.
    Burns DM, Ryan GB, Harvey CM, Nagy E, Hughes S, Murray PG, Russell NH, Fox CP, Long HM.
    Front Immunol; 2019 Aug; 10():2489. PubMed ID: 31736946
    [Abstract] [Full Text] [Related]

  • 10. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q, Burton R, Reddy V, Lucas KG.
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [Abstract] [Full Text] [Related]

  • 11. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
    Yamamoto M, Shindo M, Funayama T, Sumi C, Saito T, Toki Y, Hatayama M, Imadome KI, Mizukami Y, Okumura T.
    Medicine (Baltimore); 2022 Mar 25; 101(12):e29055. PubMed ID: 35357349
    [Abstract] [Full Text] [Related]

  • 12. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 25; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 13. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.
    Ricciardelli I, Brewin J, Lugthart G, Albon SJ, Pule M, Amrolia PJ.
    Am J Transplant; 2013 Dec 25; 13(12):3244-52. PubMed ID: 24266973
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF, Fan ZP, Luo XD, Sun J, Zhang Y, Ding YQ.
    Transpl Infect Dis; 2010 Aug 01; 12(4):284-91. PubMed ID: 20345506
    [Abstract] [Full Text] [Related]

  • 16. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.
    Cytotherapy; 2015 Sep 01; 17(9):1280-91. PubMed ID: 26276009
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Sep 01; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.
    J Immunol Methods; 2014 Jun 01; 408():101-13. PubMed ID: 24877879
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
    Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG.
    Blood; 2000 Feb 01; 95(3):807-14. PubMed ID: 10648390
    [Abstract] [Full Text] [Related]

  • 20. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS.
    Blood; 1998 Nov 01; 92(9):3318-27. PubMed ID: 9787169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.